Patents by Inventor Ryota Yoshimoto

Ryota Yoshimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10555317
    Abstract: Technical Problem To mitigate interference by using effective knowledge or information as to an interference signal. Solution to Problem There is provided a base station apparatus including a higher layer which configures, in a terminal apparatus, first interference information used in the terminal apparatus in order to mitigate interference from a cell-specific reference signal and at least one of second interference information used in the terminal apparatus in order to mitigate interference from a downlink shared channel, third interference information used in the terminal apparatus in order to mitigate interference from a downlink control channel, and fourth interference information used in the terminal apparatus in order to mitigate interference from an enhanced downlink shared channel, in which each of the second interference information, the third interference information, and the fourth interference information is configured only in a case where the first interference information is being configured.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: February 4, 2020
    Assignee: SHARP KABUSHIKI KAISHA
    Inventors: Ryota Yamada, Takashi Yoshimoto, Kazuyuki Shimezawa
  • Patent number: 10447320
    Abstract: An object is to mitigate interference by using effective knowledge or information as to an interference signal while reducing an increase in the amount of calculation. A terminal device includes a reception unit that receives downlink control information from a base station apparatus. In a case of a prescribed transmission mode, a downlink shared channel destined for the terminal apparatus is demodulated on the basis of a power offset between transmit power of the terminal apparatus and transmit power of another terminal apparatus in the downlink shared channel included in the downlink control information. Whether or not to perform interference cancellation is determined according to a value of the power offset.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 15, 2019
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Ryota Yamada, Kazuyuki Shimezawa, Takashi Yoshimoto, Hiromichi Tomeba
  • Patent number: 10404428
    Abstract: Interference is mitigated by effective knowledge and/or effective information about an interference signal. A higher layer in which a base station apparatus configures first interference information used for the terminal apparatus to mitigate interference from a cell-specific reference signal and/or second interference information used for the terminal apparatus to mitigate interference at least from a downlink shared channel; and a signal detection unit configured to mitigate the interference from the cell-specific reference signal based on the first interference information and to mitigate the interference at least from the downlink shared channel based on the second interference information.
    Type: Grant
    Filed: May 29, 2015
    Date of Patent: September 3, 2019
    Assignee: Sharp Kabushiki Kaisha
    Inventors: Ryota Yamada, Takashi Yoshimoto, Kazuyuki Shimezawa
  • Publication number: 20190159139
    Abstract: To improve throughput in a communication environment in which a large number of terminal apparatuses access. The present invention includes a receiver configured to receive information indicating whether a radio resource allocated by a base station apparatus is a grant free access resource or a scheduled access resource, as well as transmission power control information in the scheduled access resource (first transmission power control information) and transmission power control information in the grant free access resource (second transmission power control information); and a transmitter configured to transmit a transmission signal to the base station apparatus.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 23, 2019
    Inventors: RYOTA YAMADA, JUNGO GOTO, OSAMU NAKAMURA, TAKASHI YOSHIMOTO
  • Publication number: 20190141731
    Abstract: Provided are a base station apparatus, a terminal apparatus, and a communication method, in a case that uplink data transmission based on orthogonal multiple access and uplink data transmission based on non-orthogonal multiple access coexist in a cell in which many terminal apparatuses present, capable of maintaining a prescribed communication quality for the uplink data. The base station apparatus for communicating with a terminal apparatus configured to support contention based access and non-contention based access transmits, in a case that an uplink data channel received in a non-contention based manner occurs in a subframe including the contention based access region, a contention based transmission configuration change notification with respect to a subframe configured to receive the uplink data channel.
    Type: Application
    Filed: May 10, 2017
    Publication date: May 9, 2019
    Inventors: TAKASHI YOSHIMOTO, JUNGO GOTO, OSAMU NAKAMURA, RYOTA YAMADA, YASUHIRO HAMAGUCHI
  • Patent number: 6793920
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: September 21, 2004
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Publication number: 20040063701
    Abstract: The present invention relates to a novel serotonin antagonist and an anti-platelet agent, more particularly, a serotonin antagonist and an anti-platelet agent which potently and specifically inhibit the serotonin 2 receptor with low adverse side effect.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 1, 2004
    Applicant: AJINOMOTO CO., INC
    Inventors: Shingo Makino, Harumi Arisaka, Hiroshi Yamamoto, Masataka Shoji, Ryota Yoshimoto
  • Patent number: 6476049
    Abstract: A compound 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)) ethyl isonipecotic acid amide or an analog thereof or a pharmaceutically acceptable salt thereof provides a therapeutic agent for treating a patient suffering from intermittent claudication.
    Type: Grant
    Filed: August 22, 2001
    Date of Patent: November 5, 2002
    Assignee: Ajinomoto Co., Inc.
    Inventors: Takashi Komiyama, Hideaki Kihara, Ken Hirose, Hiroshi Sigematsu, Ryota Yoshimoto
  • Publication number: 20020147195
    Abstract: The present invention relates to a novel serotonin antagonist and an anti-platelet agent, more particularly, a serotonin antagonist and an anti-platelet agent which potently and specifically inhibit the serotonin 2 receptor with low adverse side effect.
    Type: Application
    Filed: March 21, 2002
    Publication date: October 10, 2002
    Applicant: AJINOMOTO CO., INC.
    Inventors: Shingo Makino, Harumi Arisaka, Hiroshi Yamamoto, Masataka Shoji, Ryota Yoshimoto
  • Publication number: 20020037906
    Abstract: A compound 1-formyl-N-(2-(4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-piperidinyl)) ethyl isonipecotic acid amide or an analog thereof or a pharmaceutically acceptable salt thereof provides a therapeutic agent for treating a patient suffering from intermittent claudication.
    Type: Application
    Filed: August 22, 2001
    Publication date: March 28, 2002
    Applicant: AJINOMOTO CO., INC.
    Inventors: Takashi Komiyama, Hideaki Kihara, Ken Hirose, Hiroshi Sigematsu, Ryota Yoshimoto
  • Publication number: 20020028204
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Application
    Filed: August 8, 2001
    Publication date: March 7, 2002
    Applicant: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Publication number: 20020019533
    Abstract: The present invention relates to a novel serotonin antagonist and an anti-platelet agent, more particularly, a serotonin antagonist and an anti-platelet agent which potently and specifically inhibit the serotonin 2 receptor with low adverse side effect.
    Type: Application
    Filed: February 8, 1999
    Publication date: February 14, 2002
    Inventors: SHINGO MAKINO, HARUMI ARISAKA, HIROSHI YAMAMOTO, MASATAKA SHOJI, RYOTA YOSHIMOTO
  • Patent number: 6303635
    Abstract: A thrombolytic drug containing cyproheptadine, a compound of the following formula or a salt thereof as the active ingredient is provided. This thrombolytic drug has a function of accelerating the release of a tissue plasminogen activator (t-PA), while exerting no effect on the release of type-1 plasminogen activator inhibitor (PAI-1) which deactivates t-PA or reducing the release thereof. wherein n represents an integer of 2 or 3, Y represents a hydrogen atom or halogen atom, and X represents a formyl group, acetyl group or hydrogen atom.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: October 16, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Yohko Kawai, Kiyoaki Watanabe, Hideaki Kihara, Hiroshi Yamamoto, Ryota Yoshimoto
  • Patent number: 6280731
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: April 26, 1999
    Date of Patent: August 28, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Patent number: 6262076
    Abstract: Disclosed is a pharmaceutical composition for use in the treatment of diabetic neuropathy, which comprises a piperidine derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein n is an integer of 2 of 3, Y is a hydrogen atom or halogen atom, and X is a formyl group, acetyl group or hydrogen atom.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: July 17, 2001
    Assignee: Ajinomoto Co., Inc.
    Inventors: Norman E. Cameron, Hideaki Kihara, Ryota Yoshimoto
  • Patent number: 5932593
    Abstract: The present invention also relates to a method of using these novel materials, and other materials, to treat or prevent a disease caused by serotonin or a method of treating or preventing platelet aggregation. The compounds used are piperidine derivatives having the formula (I): ##STR1## wherein the various substituents are defined below.
    Type: Grant
    Filed: August 25, 1997
    Date of Patent: August 3, 1999
    Assignee: Ajinomoto Co., Ltd.
    Inventors: Shingo Makino, Harumi Arisaka, Hiroshi Yamamoto, Masataka Shoji, Ryota Yoshimoto
  • Patent number: 5916805
    Abstract: A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: June 29, 1999
    Assignee: Ajinomoto Co., Inc.
    Inventors: Mitsuyo Nagano, Hiroshi Yamamoto, Morikazu Kito, Ryota Yoshimoto, Tsuyoshi Kobayashi
  • Patent number: 5856126
    Abstract: A multimer peptide from a snake venom has an activity to inhibit binding between von Willebrand factor and platelets. The multimer peptide is used to obtain a single strand peptide which does not substantially cause decrease in platelets at a minimum dose for exhibiting the activity in vivo. The single strand peptide is obtained by allowing the multimer peptide to exist together with a protein-denaturing agent, and glutathione and/or cysteine, and thereby disconnecting disulfide bonds between peptide chains for constituting the multimer peptide while substantially preserving disulfide bonds within the peptide chains. Alternatively, the single strand peptide, a mutant thereof, or a part thereof is produced by genetic engineering techniques by using genes coding for them.
    Type: Grant
    Filed: March 20, 1996
    Date of Patent: January 5, 1999
    Assignee: Ajinomoto Co., Inc.
    Inventors: Naoyuki Fukuchi, Hiroshi Yamamoto, Mitsuyo Nagano, Morikazu Kito, Akiko Tanaka, Koichi Ishii, Tsuyoshi Kobayashi, Ryota Yoshimoto
  • Patent number: 5250681
    Abstract: A piperidine compound of the formula (I): ##STR1## wherein A is a fused aromatic ring; R is hydrogen, chloro or methoxy; X is (CH.sub.2).sub.n, which may be substituted, in which n is 0 or an integer of 1 to 10, --CH.dbd.CH--, --C.dbd.C--, --O--, --S--, --NH--, --N(COCH.sub.3)--, --N(COOC.sub.2 H.sub.5)--, --N(CHO)--, --N(CH.sub.3)--, --CO--, --SO--, or --SO.sub.2 --; Y is --CH.dbd.CH--, --CH.sub.2 CH.sub.2 --, --CH.sub.2 CO--, --O--, --S--, --NH--, --OCH.sub.2 --, --SCH.sub.2 --, --NHCH.sub.2 --, --CH(OH)CH.sub.2 -- or --CH(OH)CH(OH)--; and Q is substituted or unsubstituted n-hexyl, carboxypropyl, ethoxycarbonylpropyl, cyanopropyl, cyclohexyl, phenyl, indanyl, naphthyl, tetrahydronaphthyl, benzocycloheptyl, piperidinyl, tetrahydroisoquinolinyl, indolyl, pyrolyl, furyl, thienyl, thiazolyl, oxazolyl or N-methylpyrolyl, wherein any one or more of the --(CH.sub.2)-groups of the hexyl, carboxypropyl, ethoxycarbonylpropyl and cyanopropyl groups may be replaced by --CH.dbd.CH--, --C.dbd.
    Type: Grant
    Filed: February 15, 1991
    Date of Patent: October 5, 1993
    Assignee: Ajinomoto Co., Inc.
    Inventors: Masataka Shoji, Kozo Toyota, Chikahiko Eguchi, Ryota Yoshimoto, Yoshikatsu Koyama, Hideki Domoto, Akira Kamimura
  • Patent number: RE38257
    Abstract: A piperidine compound of the formula (I): wherein A is a fused aromatic ring; R is hydrogen, chloro or methoxy; X is (CH2)n, which may be substituted, in which n is 0 or an integer of 1 to 10, —CH≡CH—, —C≡C—, —O—, —S—, —NH—, —N(COCH3)—, —N(COOC2H5)—, —N(CHO)—, —N(CH3)—, —CO—, —SO—, or —SO2—; Y is —CH≡CH—, —CH2CH2—, —CH2CO—, —O—, —S—, —NH—, —OCH2—, —SCH2—, —NHCH2—, —CH(OH)CH2— or —CH(OH)CH(OH)—; and Q is substituted or unsubstituted n-hexyl, carboxypropyl, ethoxycarbonylpropyl, cyanopropyl, cyclohexyl, phenyl, indanyl, naphthyl, tetrahydronaphthyl, benzocycloheptyl, piperidinyl, tetrahydroisoquinolinyl, indolyl, pyrolyl, furyl, thienyl, thiazolyl, oxazolyl or N-methylpyrolyl, wherein any one or more of t
    Type: Grant
    Filed: February 10, 1999
    Date of Patent: September 23, 2003
    Assignee: Ajinomoto Co., Inc.
    Inventors: Masataka Shoji, Kozo Toyota, Chikahiko Eguchi, Ryota Yoshimoto, Yoshikatsu Koyama, Hideki Domoto, Akira Kamimura